An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Study sponsor: Denali Therapeutics Inc. · DNLI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-06Estimated
Enrollment · participants99Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.